Brano Therapeutics

Brano Therapeutics, based in Singapore, specializes in developing innovative therapeutic solutions for cardio-metabolic diseases, particularly focusing on Heart Failure with Preserved Ejection Fraction (HFpEF). Founded in 2025 and headquartered in Singapore, Brano Therapeutics focuses on developing therapeutic solutions for heart failure conditions. The company has undergone no significant pivots in its business strategy and does not have any known subsidiaries. Its founder's history is not detailed in the available data.

Brano Therapeutics raised USD 6. 8 mn in Seed funding on May 6, 2026, co-led by Trinity Innovation Bioventure Singapore and SEEDS Capital, with participation from SGInnovate and Live Ventures. This funding was aimed at advancing the development of heart failure treatments and clinical trials. Brano Therapeutics specializes in the development of innovative therapeutic solutions aimed at addressing unmet medical needs in cardio-metabolic diseases, particularly focusing on Heart Failure with Preserved Ejection Fraction (HFpEF).

The company’s primary product involves small-molecule inhibitors designed to restore disrupted metabolic pathways, ultimately aiming to improve patient outcomes for those suffering from HFpEF. This product is directed towards healthcare providers and institutions involved in cardiology and metabolic disease management. Brano Therapeutics targets markets across Asia and selectively in North America and Europe, catering to a diverse client base that includes hospitals, specialty clinics, and pharmaceutical partners seeking advanced treatment options for complex cardiovascular conditions. The revenue model of Brano Therapeutics is structured around partnerships and collaborations with healthcare institutions and pharmaceutical companies, focusing on the clinical development and commercialization of their therapeutic products.

Revenue streams are expected to arise from licensing agreements, milestone payments, and potential royalties from successful product sales. The firm's flagship small-molecule inhibitors are positioned for B2B transactions, targeting hospitals and healthcare systems that integrate these therapies into their treatment protocols. Specific pricing plans and transaction details are tailored to the nature of the partnerships established, aligning with the strategic goals of both Brano Therapeutics and its collaborators in the healthcare sector. Brano Therapeutics plans to leverage its recent Seed funding of USD 6.

8 mn raised in May 2026 to advance its heart failure treatments and move its lead therapies into clinical trials. The company is also looking to expand into markets across North America and Europe by the end of 2027, aligning its product development initiatives with the growing demand for innovative treatments in cardiology.